Cirrhosis Research Studies
Investigators
Open Research Studies for Cirrhosis
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
Principle Investigator: Eric Orman, MD
Duration: 1 year
Patient Population: Patients with refractory ascites
Interested in this study? Please contact the following coordinator:
Holly King
ALC Database
Enrolling: Yes
Principle Investigator: Craig Lammert, MD
Duration: 1 visit
Patient Population: Alcoholic liver cirrhosis, no viral hepatitis, pre/post transplant.
Interested in this study? Please contact the following coordinator:
Kelsey Green
greenke@iu.edu
(317) 278-9292
ALTUS: Performance of a Multi-Target Hepatocellular Carcinoma (HCC) Test in Subjects with Increased Risk
Enrolling: Yes
Principle Investigator: Naga Chalasani, MD
Duration: 6-8 months
Patient Population: Adults 18+, Child-Pugh A or B, no known cancer diagnosis < 5 years
Interested in this study? Please contact the following coordinator:
Jake McCarty
jacmccar@iu.edu
(317) 278-6305
The Cirrhosis Medical Home
Enrolling: Yes
Principle Investigator: Eric Orman, MD
Duration: Patients are enrolled for 6 months - total study duration is 2 years.
Patient Population: Patients with cirrhosis who have recently been discharged from the hospital and their caregivers.
Interested in this study? Please contact the following coordinator:
Jake McCarty
(317) 278-6305
Cirrhosis Readmit. Inpatient
Enrolling: Yes
Principle Investigator: Archita Desai, MD
Duration: 3 - 5 years
Patient Population: Inpatients over the age of 18 with cirrhosis.
Interested in this study? Please contact the following coordinator:
Jake McCarty
(317) 278-6305
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Enrolling: Yes
Principle Investigator: Marwan Ghabril, MD
Duration: 24 week treatment period with 4 week screening and 4 week follow-up
Patient Population: Adults with cirrhosis and history of hepatic encephalopathy
Drug(s): AXA1665/Placebo
Interested in this study? Please contact the coordinator below:
Jennifer Terrell
(317) 278-6266
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C) RNLC3131 and RNLC3132
Enrolling: No
Principle Investigator: Marwan Ghabril, MD
Duration: 72 week treatment period with 4 week screning and 4 week follow-up
Patient Population: Adults with cirrhosis and no history of hepatic encephalopathy
Drug(s): Rifaximin SSD/placebo
Interested in this study? Please contact the coordinator below:
Jennifer Terrell
(317) 278-6266
Galectin - Phase 2b/3
Enrolling: TBD
Principle Investigator: Raj Vuppalanchi, MD
Duration: 52 week treatment period with possibility of 52 additional weeks.
Patient Population: Patients 18-75 years old with NASH cirrhosis and no varices.
Drug(s): Belapectin every 2 week infusion.
Interested in this study? Please contact the coordinator below:Mandy Cruz
mandcruz@iu.edu
(317) 278-6215
ICU Study
Enrolling: No
Principle Investigator: Kavish Patidar, DO
Duration: 5 years
Patient Population: Adults over the age of 18 with a diagnosis of cirrhosis admitted to the ICU.
Midwest Cirrhosis Consortium
Enrolling: Yes
Principle Investigators: Marwan Ghabril, MD and Eric Orman, MD
Duration: 1 visit
Patient Population: Adults over the age of 18 with a diagnosis of cirrhosis admitted to the ICU, PCU and wards as an inpatient.
Inerested in this study? Please contact the following coordinator:
Jake McCarty
jacmccar@iu.edu
(317) 278-6305
Orman Fitness Pilot Study
Enrolling: Yes
Principle Investigator: Eric Orman, MD
Duration: 3 months
Patient Population: 18 and older
Interested in this study? Please contact the following coordinator:
Kelsey Green
(317) 278-9292
Safety and Efficacy of Ketogenic Diet for PromotingWeight Loss in Obese Individuals with Compensated NASH Cirrhosis
Enrolling: Yes
Principle Investigator: Raj Vuppalanchi, MD
Duration: 16 weeks
Patient Population: Patients over the age of 18 with a diagnosis of NASH cirrhosis with a BMI >30kg/m2.
Interested in this study? Please contact the following coordinator:
Emily Smith
es37@iu.edu
(317) 274-1692
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
Principle Investigator: Eric Orman, MD
Duration: 1 year
Patient Population: Patients with refractory ascites.
Drug(s): Terlipressin
Interested in this study? Please contact the following coordinator:
Holly King
(317) 278-6200
Tocotrienol
Principle Investigator: Kavish Patidar, DO
Duration: 5 years
Patient Population: Adults over the age 18 with a diagnosis of cirrhosis admitted to the ICU.
Interested in this study? Please contact the following coordinator:
Anna Smith
(317) 962 - 9978
Closed Cirrhosis Studies
-
Cirrhotic Database
Enrolling: No
Duration: 1 visit.
-
UCD Database
Enrolling: No
Duration: 1 visit.
-
HRQoL Comparison Study
Enrolling: No
Principle Investigator: Naga Chalasani, MD
Duration: 3 - 5 years
Patient Population: Patients that are over 18 years old with liver disease
-
Cirrhosis OP QoLEnrolling: No
Principle Investigator: Archita Desai, MD
Duration: 3 -5 years
Patient Population: Patients over the age of 18 with cirrhosis.